Calian Group (TSE:CGY) received a positive boost from Ventum Financial, which raised its price target from C$58.00 to C$62.00 in a recent research report. This adjustment, made on Thursday, indicates a potential upside of approximately 15.48% from the stock’s current valuation. Ventum Financial has assigned a “buy” rating for Calian, reflecting confidence in the company’s future performance.
Several other analysts have also revised their price targets for Calian Group. Canaccord Genuity Group increased its target from C$60.00 to C$63.00, while maintaining a “buy” rating. Similarly, the Royal Bank of Canada raised its target from C$58.00 to C$66.00, assigning an “outperform” rating. CIBC further added to the positive sentiment by increasing its target from C$59.00 to C$62.00, also granting an “outperform” rating.
Analyst Consensus and Market Outlook
In contrast, Desjardins adjusted its target price downward from C$62.00 to C$59.00 but still maintains a “buy” recommendation. Overall, according to data from MarketBeat.com, five analysts have rated Calian Group with a “buy” designation, leading to a consensus rating of “Buy” and an average price target of C$63.80.
Such optimistic forecasts reflect Calian Group’s diverse operational segments, which include Advanced Technologies, Health, Learning, and Information Technology. Notably, the Health segment generates the majority of the company’s revenue. Calian serves various industries such as health, defence, security, aerospace, engineering, AgTech, and IT. Its Health services encompass Clinical Services, Nursing Services, Psychological Services, and Medical Property Management.
As analysts continue to evaluate Calian Group’s performance, investors may find the upcoming months pivotal for potential growth, driven by the company’s strong positioning in critical sectors.
